We then analyzed the immune checkpoints (Figures 10C,D), we can see from the picture nearly every immune checkpoint has been revealed to be more active in the low-risk BC group, including CD274 (PDL1), LAG3, PDCD1 (PD1), TNFRSF18 and LGALS9, suggesting that these individuals may be more responsive to immunotherapy. This evidence concerns the gene CD274 and breast cancer.